This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
OncoMed Pharmaceuticals, Inc., a clinical development-stage biotechnology company, discovers and develops protein therapeutics targeting cancer stem cells (CSCs).View OMED key stats
OncoMed Pharmaceuticals Inc - OMED - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates OncoMed Pharmaceuticals Inc as a
Hold with a ratings score of C.
Report Snippet: We rate ONCOMED PHARMACEUTICALS (OMED) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. Among the primary strengths of the company is its solid financial position based on a variety of debt and liquidity measures that we have evaluated. At the same time, however, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow.